Litcius/Paper detail

Hyperglycemia and insulin resistance in COVID-19 versus non-COVID critical illness: Are they really different?

Lies Langouche, Greet Van den Berghe, Jan Gunst

2021Critical Care18 citationsDOIOpen Access PDF

Abstract

sponsorship: JG receives a postdoctoral research fellowship from the University Hospitals Leuven, and C2 project funding from KU Leuven (C24/17/070). GVdB and LL, via the KU Leuven, receive long-term structural research support from the Methusalem Program funded by the Flemish Government (METH14/06). The authors receive research funding from the Research Foundation Flanders (G069421N to LL and GVdB; T003617N to GVdB and JG). GVdB holds an Advanced Research Grant [AdvG 2017-785809] from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program. (University Hospitals Leuven, KU Leuven|C24/17/070, Methusalem Program - Flemish Government|METH14/06, Research Foundation Flanders|G069421N, Research Foundation Flanders|T003617N, European Research Council (ERC) under the European Union|AdvG 2017-785809, KU Leuven)

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Critical illness2019-20 coronavirus outbreakInsulin resistanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicBetacoronavirusIntensive care medicineCoronavirus InfectionsCritically illVirologyInsulinInternal medicineInfectious disease (medical specialty)DiseaseOutbreakHyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and ResearchDiabetes and associated disorders